Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rebastinib + Carboplatin in Advanced Solid Tumors
NCT03717415Phase 2Terminated
- Sponsor
- Deciphera Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rebastinib in solid tumor (advanced stage), triple-negative breast cancer (TNBC), ovarian cancer and 1 more (9 arms), sponsored by Deciphera Pharmaceuticals. Primary endpoints: Number of Participants With Adverse Events up to 2.32 years and Objective Response Rate up to 1.53 years. Started Jan 2019; status: terminated.
02
Drugs
rebastinib
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)ovarian cancermesothelioma
Beyond the preview
Go deeper on NCT03717415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03717415.